Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levocetirizine
Drug ID BADD_D01272
Description Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine].[L7694] Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Indications and Usage Levocetirizine is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) in adults and children 6 years of age and older.
Marketing Status Prescription; OTC; Discontinued
ATC Code R06AE09
DrugBank ID DB06282
KEGG ID D07402
MeSH ID C472067
PubChem ID 1549000
TTD Drug ID D0M8PW
NDC Product Code Not Available
Synonyms levocetirizine | levocetrizine | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- | (2-(4-((R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid | levocetirizine hydrochloride | Xusal | levocetirizine dihydrochloride | (2-(4-((R)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride | cetirizine (R)-form dihydrochloride | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride | Xyzal | UCB-28556
Chemical Information
Molecular Formula C21H25ClN2O3
CAS Registry Number 130018-77-8
SMILES C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperhidrosis23.02.03.004; 08.01.03.0280.000585%
Hyperprolactinaemia05.03.01.0020.000585%Not Available
Hypersensitivity10.01.03.003--
Hyponatraemia14.05.04.0020.000585%
Hypotension24.06.03.002--
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Infection11.01.08.0020.000229%Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intentional self-injury19.12.01.002; 12.01.08.0360.000585%Not Available
Interstitial lung disease22.01.02.003; 10.02.01.0330.000877%Not Available
Irritability19.04.02.013; 08.01.03.0110.000585%
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.0300.000585%Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.001169%
Lip oedema23.04.01.006; 10.01.05.004; 07.05.04.0040.000585%Not Available
Lip swelling07.05.04.005; 23.04.01.007; 10.01.05.0050.002339%Not Available
Liver disorder09.01.08.0010.000877%Not Available
Liver function test abnormal13.03.01.0130.001462%Not Available
Loss of consciousness17.02.04.0040.004677%Not Available
Malaise08.01.01.0030.002046%
Metrorrhagia21.01.01.0060.000585%Not Available
Movement disorder17.01.02.010--Not Available
Muscle spasms15.05.03.0040.000877%
Myalgia15.05.02.001--
Myoclonus17.02.05.008--Not Available
Nail discolouration23.02.05.0010.000585%
Nasopharyngitis11.01.13.002; 22.07.03.002--Not Available
Nausea07.01.07.001--
Nightmare19.02.03.0030.000585%Not Available
Obsessive thoughts19.06.05.0010.000585%Not Available
Oculogyric crisis17.01.03.002; 06.05.02.002--Not Available
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages